239 related articles for article (PubMed ID: 23922187)
1. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.
Grant BW; Jung SH; Johnson JL; Kostakoglu L; Hsi E; Byrd JC; Jones J; Leonard JP; Martin SE; Cheson BD
Cancer; 2013 Nov; 119(21):3797-804. PubMed ID: 23922187
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
Czuczman MS; Leonard JP; Jung S; Johnson JL; Hsi ED; Byrd JC; Cheson BD
Ann Oncol; 2012 Sep; 23(9):2356-2362. PubMed ID: 22357442
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract][Full Text] [Related]
4. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
5. Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
Tomás JF; Montalbán C; De Sevilla AF; Martínez-López J; Díaz N; Canales M; Martínez R; Sánchez-Godoy P; Caballero MD; Peñalver J; Prieto E; Salar A; Burgaleta C; Queizán JA; Bajo R; De Oña R; De La Serna J
Leuk Lymphoma; 2011 Mar; 52(3):409-16. PubMed ID: 21275633
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).
Rosenbaum CA; Jung SH; Pitcher B; Bartlett NL; Smith SM; Hsi E; Wagner-Johnston N; Thomas SP; Leonard JP; Cheson BD
Br J Haematol; 2019 Apr; 185(1):53-64. PubMed ID: 30723894
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
Strauss SJ; Morschhauser F; Rech J; Repp R; Solal-Celigny P; Zinzani PL; Engert A; Coiffier B; Hoelzer DF; Wegener WA; Teoh NK; Goldenberg DM; Lister TA
J Clin Oncol; 2006 Aug; 24(24):3880-6. PubMed ID: 16864854
[TBL] [Abstract][Full Text] [Related]
8. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
Fayad L; Offner F; Smith MR; Verhoef G; Johnson P; Kaufman JL; Rohatiner A; Advani A; Foran J; Hess G; Coiffier B; Czuczman M; Giné E; Durrant S; Kneissl M; Luu KT; Hua SY; Boni J; Vandendries E; Dang NH
J Clin Oncol; 2013 Feb; 31(5):573-83. PubMed ID: 23295790
[TBL] [Abstract][Full Text] [Related]
9. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
Blum KA; Polley MY; Jung SH; Dockter TJ; Anderson S; Hsi ED; Wagner-Johnston N; Christian B; Atkins J; Cheson BD; Leonard JP; Bartlett NL
Cancer; 2019 Oct; 125(19):3378-3389. PubMed ID: 31174236
[TBL] [Abstract][Full Text] [Related]
11. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma.
Leonard JP; Schuster SJ; Emmanouilides C; Couture F; Teoh N; Wegener WA; Coleman M; Goldenberg DM
Cancer; 2008 Nov; 113(10):2714-23. PubMed ID: 18853418
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.
Lansigan F; Barak I; Pitcher B; Jung SH; Cheson BD; Czuczman M; Martin P; Hsi E; Schöder H; Smith S; Bartlett NL; Leonard JP; Blum KA
Cancer Med; 2019 Jan; 8(1):165-173. PubMed ID: 30575311
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial.
Zinzani PL; Khuageva NK; Wang H; Garicochea B; Walewski J; Van Hoof A; Soubeyran P; Caballero D; Buckstein R; Esseltine DL; Theocharous P; Enny C; Zhu E; Elsayed YA; Coiffier B
J Hematol Oncol; 2012 Oct; 5():67. PubMed ID: 23088650
[TBL] [Abstract][Full Text] [Related]
14. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
15. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.
Hainsworth JD; Greco FA; Raefsky EL; Thompson DS; Lunin S; Reeves J; White L; Quinn R; DeBusk LM; Flinn IW
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):277-83. PubMed ID: 24679633
[TBL] [Abstract][Full Text] [Related]
16. Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.
Illidge TM; McKenzie HS; Mayes S; Bates A; Davies AJ; Pettengell R; Stanton L; Cozens K; Hampson G; Dive C; Zivanovic M; Tipping J; Gallop-Evans E; Radford JA; Johnson PW
Br J Haematol; 2016 Apr; 173(2):274-82. PubMed ID: 26849853
[TBL] [Abstract][Full Text] [Related]
17. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.
Micallef IN; Maurer MJ; Wiseman GA; Nikcevich DA; Kurtin PJ; Cannon MW; Perez DG; Soori GS; Link BK; Habermann TM; Witzig TE
Blood; 2011 Oct; 118(15):4053-61. PubMed ID: 21673350
[TBL] [Abstract][Full Text] [Related]
18. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial.
Witzens-Harig M; Hensel M; Unterhalt M; Herfarth K
BMC Cancer; 2011 Feb; 11():87. PubMed ID: 21352561
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
[TBL] [Abstract][Full Text] [Related]
20. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.
Pastore A; Jurinovic V; Kridel R; Hoster E; Staiger AM; Szczepanowski M; Pott C; Kopp N; Murakami M; Horn H; Leich E; Moccia AA; Mottok A; Sunkavalli A; Van Hummelen P; Ducar M; Ennishi D; Shulha HP; Hother C; Connors JM; Sehn LH; Dreyling M; Neuberg D; Möller P; Feller AC; Hansmann ML; Stein H; Rosenwald A; Ott G; Klapper W; Unterhalt M; Hiddemann W; Gascoyne RD; Weinstock DM; Weigert O
Lancet Oncol; 2015 Sep; 16(9):1111-1122. PubMed ID: 26256760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
